Quest Diagnostics Delivers Q4 Earnings Beat: The Details

Quest Diagnostics Inc DGX shares are trading higher Thursday after the company reported better-than-expected financial results for the fourth quarter.

What Happened: Quest Diagnostics reported fourth-quarter revenue of $2.62 billion, beating analyst estimates of $2.58 billion, according to Benzinga Pro. The company reported fourth-quarter adjusted earnings of $2.23 per share, beating estimates of $2.19 per share.

Total revenue was up 14.5% year-over-year, while earnings grew 14.7% year-over-year.

Quest’s board authorized a 6.7% increase to the company’s quarterly dividend from 75 cents to 80 cents. The dividend will be payable on April 21 to shareholders of record as of April 7.

“In the fourth quarter, we delivered impressive revenue growth of nearly 15%, including approximately 5% organic growth, while also improving our profitability,” said Jim Davis, chairman, president and CEO of Quest Diagnostics.

“For the full year, we drove revenue growth of close to 7%, including approximately 3% from organic growth. Our team completed eight acquisitions, including LifeLabs in Canada, expanded our advanced diagnostics portfolio, and extended our geographic and market reach with new clinical, consumer and health plan customers.”

See Also: Intel Q4 Earnings Preview: CEO Search, PC Demand, Spinoffs On Watch

Outlook: Quest Diagnostics expects full-year 2025 revenue to be in the range of $10.7 billion to $10.85 billion. The company expects earnings to be in the range of $8.34 to $8.59 per share, versus estimates of $8.82 per share.

“Our guidance for 2025 reflects our confidence in the core strength of our business, continuing robust utilization, and the momentum from acquisitions completed in 2024,” Davis added.

DGX Price Action: Quest Diagnostics shares were up 6.01% at $164.78 at the time of publication, according to Benzinga Pro.

This illustration was generated using artificial intelligence via Midjourney.